Compare · ELV vs TLSI
ELV vs TLSI
Side-by-side comparison of Elevance Health Inc. (ELV) and TriSalus Life Sciences Inc. (TLSI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and TLSI operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $92.17B, about 449.3x TLSI ($205.1M).
- Over the past year, ELV is up 5.5% and TLSI is down 35.4% - ELV leads by 40.9 points.
- TLSI has been more active in the news (8 items in the past 4 weeks vs 4 for ELV).
- ELV has more recent analyst coverage (23 ratings vs 6 for TLSI).
PerformanceELV+5.54%TLSI-35.38%
2025-06-10+0.00%2026-06-10
- Company
- Elevance Health Inc.
- TriSalus Life Sciences Inc.
- Price
- $405.00-4.56%
- $3.58+7.19%
- Market cap
- $92.17B
- $205.1M
- 1M return
- +6.11%
- -21.32%
- 1Y return
- +5.54%
- -35.38%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 4
- 8
- Recent ratings
- 23
- 6
ELV
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest ELV
- Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Elevance Health Expands Access to Digital Tools, Helping Bridge the Healthcare Digital Divide
- CAO & Controller Penczek Ronald W exercised 1,531 shares at a strike of $294.30 and sold $617,192 worth of shares (1,531 units at $403.13) (SEC Form 4)
- Elevance Health upgraded by Deutsche Bank with a new price target
- Director Schulman Amy W was granted 563 shares, increasing direct ownership by 258% to 781 units (SEC Form 4)
- Director Schneider Ryan M. was granted 563 shares, increasing direct ownership by 9% to 7,163 units (SEC Form 4)
- Director Peru Ramiro G was granted 563 shares, increasing direct ownership by 6% to 9,908 units (SEC Form 4)
- Director Neri Antonio F was granted 563 shares, increasing direct ownership by 11% to 5,488 units (SEC Form 4)
- Director Jallal Bahija was granted 563 shares, increasing direct ownership by 12% to 5,351 units (SEC Form 4)
- Director Hay Lewis Iii was granted 563 shares, increasing direct ownership by 5% to 12,070 units (SEC Form 4)
Latest TLSI
- TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
- Amendment: SEC Form SCHEDULE 13G/A filed by TriSalus Life Sciences Inc.
- Chief Commercial Officer Marshak Richard sold $1,450 worth of shares (543 units at $2.67), decreasing direct ownership by 0.43% to 125,101 units (SEC Form 4) to cover withholding tax
- Director Wahlstrom Mats bought $151,800 worth of shares (60,000 units at $2.53), increasing direct ownership by 69% to 147,555 units (SEC Form 4)
- Director Stansky Michael P bought $1,525,000 worth of shares (610,000 units at $2.50), increasing direct ownership by 49% to 1,240,722 units (SEC Form 4)
- Chief Financial Officer Patience David bought $17,253 worth of shares (7,100 units at $2.43), increasing direct ownership by 3% to 275,757 units (SEC Form 4)
- CEO and President Szela Mary T bought $102,776 worth of shares (39,682 units at $2.59), increasing direct ownership by 4% to 1,065,215 units (SEC Form 4) to cover withholding tax
- Director Gordon Gary B. bought $24,600 worth of shares (10,000 units at $2.46), increasing direct ownership by 16% to 72,510 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by TriSalus Life Sciences Inc.
- Director Gordon Gary B. was granted 52,754 shares, increasing direct ownership by 541% to 62,510 units (SEC Form 4)